This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Cardiovascular Interventions, Other  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy, Other  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2007;297:2064-2067.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

NEW ORLEANS—The first generation of drug-eluting stents has come under fire in recent months for inappropriate use in some patients with stable coronary artery disease and for possibly promoting late-event thrombosis. But stents remain essential tools for cardiologists treating patients with a variety of coronary problems, and researchers and manufacturers continue to design and test new versions, with the aim of improving outcomes while diminishing adverse events.

Results from an array of drug-eluting stent trials were presented here in March at the annual meeting of the American College of Cardiology. Among the new types of stents discussed were those with a thin metal platform using a new drug; a biodegradable stent that may solve the late-event thrombosis concern; a stent using two drugs; and a stent that captures endothelial progenitor cells (EPCs).

This bioabsorbable stent is one of a number of new stents that are being studied . . . [Full Text of this Article]

THE DISAPPEARING STENT



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?